References
- Nelson, P.E., Dignani, M.C. and Anaissie, E.J. (1994) "Taxonomy, biology, and clinical aspects of Fusarium species", Clinical Micro-biology, 7(4), 479 — 504.
- Boutati, E.I. and Anaissie, E.J. (1997) "Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for manage-ment", Blood, 90(3), 999–1008.
- Torres, H. and Kontoyiannis, D.P. (2003) Hyalohyphomycosis (other than Aspergillosis and Penicilliosis). In: Oxford Textbook of Clinical Mycology, 1st edn, edited by W.E. Dismukes, P.G. Pappas and JD Sobel, Pp. 252–270. New York, NY: Oxford University Press.
- Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., et al. (2002) "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", Clinical Infectious Diseases, 34(1), 7–14.
- Walsh, Ti., Hiemenz, J.W., Seibel, N.L., Perfect, J.R., Horwith, G., Lee, L., et al. (1998) "Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases", Clinical Infectious Diseases, 26(6), 1383 — 1396.
- Walsh, T.J., Lutsar, I., Driscoll, T., Dupont, B., Roden, M., Ghahramani, P., et al. (2002) "Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children", Pediatric Infectious Disease Journal, 21(3), 240–248.
- Denning, D.W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., et al. (2002) "Efficacy and Safety of Voriconazole in the treatment of acute invasive aspergillosis", Clinical Infectious Diseases, 34(5), 563–571.
- Hachem, R.Y., Raad, II., Afif, CM., Negroni, R., Graybill, J., Hadley, S., et al. (2000) "An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy", Programs and abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. J–1109.
- Maertens, J., Raad, I., Petrikkos, G., Selleslag, D., Petersen, F., Sable, C., et al. (2002) "Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant (I) to other antifungal agents: Analysis of 90 patients", Programs and abstracts, 41" Interscience Conference on Antimicrobial Agents and Chemotherapy. M–860.
- Anaissie, E.J., Kontoyiannis, D.P., Vartivarian, S., Kantarjian, H.M., O'Brien, S., Giralt, S.A., et al. (1993) "Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: Experience with SCH 39304", Clinical Infectious Diseases, 17\(Suppl 6), 1022— 1031.
- Walsh, T.J., Francesconi, A., Kasai, M. and Chanock, Si. (1995) "PCR and single-strand conformational polymorphism for recogni-tion of medically important opportunistic fungi", Journal of Clinical Microbioliogy, 33(12), 3216— 3220.
- Winn, R.M., Maloukou, A., Gil-Lamiagnere, C., Panteliadis, C. and Roilides, E. (2001) "Interferon-gamma and granulocyte-macrophage colony stimulating factor enhance hyphal damage of Aspergillus and Fusarium spp by human neutrophils", Program and abstracts of the 41th Interscience Conference on Antimicrobial Agents and Chemotherapy. J–134.